Loading
Life sciences · Journal article
Pharmaceutical Biology · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Context. High-quality evidence on Lianhua Qingwen (LHQW) for treating influenza in children remains limited.Objective. To evaluate the efficacy and safety of LHQW in children aged 3-14 years with influenza, compared with oseltamivir.Materials and methods. In this multicenter, randomized, double-blind, positive parallel-controlled trial, participants were randomly assigned (1:1) to receive either LHQW + oseltamivir placebo or oseltamivir + LHQW placebo. The primary outcome was clinical recovery time. Secondary outcomes included time to defervescence, symptom scores on the Canadian Acute Respiratory Illness and Flu Scale, the incidence of complications and severe/critical influenza, and the improvement rates for individual influenza symptoms. Safety outcomes were assessed based on adverse events.Results. A total of 520 participants were randomized (260 per group). Baseline characteristics were comparable. Median clinical recovery time was 5 days in both groups, with similar clinical recovery rates (71.5% vs. 71.2%; HR: 1.04, 95% CI: 0.84-1.29; one-sided p < 0.025). Median time to defervescence was shorter with LHQW (24 h vs. 30 h, p < 0.05). LHQW showed higher improvement rates for cough (56.9% vs. 45.5%) and sore throat (90.9% vs. 74.2%) (both p < 0.05). No severe or critical influenza occurred in the LHQW group. Adverse events incidence was similar between groups (p > 0.05).Discussion. LHQW may offer a safe and effective alternative to oseltamivir for pediatric influenza, with particular benefits for defervescence, cough, and sore throat.Conclusions. LHQW was non-inferior to oseltamivir in clinical recovery time and resulted in faster defervescence and greater improvement in cough and sore throat, with comparable safety.Clinical trial registration number. ChiCTR1900028390 (Chinese Clinical Trial Registry, Dec. 20, 2019).